GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (MEX:ALT1) » Definitions » Cyclically Adjusted PB Ratio

Altimmune (MEX:ALT1) Cyclically Adjusted PB Ratio : 0.09 (As of May. 25, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Altimmune Cyclically Adjusted PB Ratio?

As of today (2025-05-25), Altimmune's current share price is MXN127.00. Altimmune's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was MXN1,483.36. Altimmune's Cyclically Adjusted PB Ratio for today is 0.09.

The historical rank and industry rank for Altimmune's Cyclically Adjusted PB Ratio or its related term are showing as below:

MEX:ALT1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.14   Max: 8.07
Current: 0.1

During the past years, Altimmune's highest Cyclically Adjusted PB Ratio was 8.07. The lowest was 0.02. And the median was 0.14.

MEX:ALT1's Cyclically Adjusted PB Ratio is ranked better than
88.47% of 668 companies
in the Biotechnology industry
Industry Median: 1.495 vs MEX:ALT1: 0.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Altimmune's adjusted book value per share data for the three months ended in Mar. 2025 was MXN37.371. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN1,483.36 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Altimmune Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Altimmune's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Cyclically Adjusted PB Ratio Chart

Altimmune Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.12 0.22 0.17 0.12

Altimmune Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.10 0.10 0.12 0.09

Competitive Comparison of Altimmune's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Altimmune's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Altimmune's Cyclically Adjusted PB Ratio falls into.


;
;

Altimmune Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Altimmune's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=127.00/1483.36
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Altimmune's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=37.371/134.9266*134.9266
=37.371

Current CPI (Mar. 2025) = 134.9266.

Altimmune Quarterly Data

Book Value per Share CPI Adj_Book
201506 1,350.685 100.684 1,810.054
201509 1,388.935 100.392 1,866.735
201512 1,331.535 99.792 1,800.332
201603 1,251.098 100.470 1,680.161
201606 2,076.324 101.688 2,755.006
201609 11,932.276 101.861 15,805.671
201612 2,937.558 101.863 3,891.068
201703 1,484.201 102.862 1,946.859
201706 2,671.907 103.349 3,488.287
201709 1,700.931 104.136 2,203.865
201712 1,283.114 104.011 1,664.497
201803 992.608 105.290 1,272.009
201806 565.180 106.317 717.270
201809 430.053 106.507 544.807
201812 104.497 105.998 133.016
201903 85.550 107.251 107.626
201906 80.293 108.070 100.247
201909 63.564 108.329 79.170
201912 56.068 108.420 69.775
202003 63.958 108.902 79.243
202006 69.125 108.767 85.750
202009 133.393 109.815 163.896
202012 120.968 109.897 148.519
202103 131.673 111.754 158.975
202106 120.998 114.631 142.420
202109 108.377 115.734 126.349
202112 99.650 117.630 114.303
202203 85.167 121.301 94.734
202206 84.397 125.017 91.087
202209 83.889 125.227 90.387
202212 73.424 125.222 79.114
202303 61.342 127.348 64.993
202306 54.603 128.729 57.232
202309 49.561 129.860 51.495
202312 46.616 129.419 48.600
202403 40.482 131.776 41.450
202406 39.332 132.554 40.036
202409 36.925 133.029 37.452
202412 35.601 133.157 36.074
202503 37.371 134.927 37.371

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Altimmune  (MEX:ALT1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Altimmune Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Altimmune's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Altimmune Business Description

Industry
Traded in Other Exchanges
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines